(Total Views: 4012)
Posted On: 05/01/2017 12:05:09 PM
Post# of 1460
From the article: " In a field where universal failure is expected, Bryostatin-1
showed an improvement in memory. Our opinion, the study met its objective of
showing that the drug has sufficient activity to move to a larger study with a longer treatment period."
https://aegis.bluematrix.com/sellside/EmailDo...ource=mail
I agree with their assessment. In the short term the question is going to be whether the company is able to stabilize stock price here and get funding to continue.
I think it was a grave error for them to do a 3-month trial in a long-term slow-decline disease like Alzheimer's. Hindsight is perfect, yet when I first heard that it was only a 3-month trial, I wondered why they were doing it for such a short timeframe.
showed an improvement in memory. Our opinion, the study met its objective of
showing that the drug has sufficient activity to move to a larger study with a longer treatment period."
https://aegis.bluematrix.com/sellside/EmailDo...ource=mail
I agree with their assessment. In the short term the question is going to be whether the company is able to stabilize stock price here and get funding to continue.
I think it was a grave error for them to do a 3-month trial in a long-term slow-decline disease like Alzheimer's. Hindsight is perfect, yet when I first heard that it was only a 3-month trial, I wondered why they were doing it for such a short timeframe.
(0)
(0)
